Efficacy of Salvage Radiotherapy Plus 2-Year Androgen Suppression for Postradical Prostatectomy Patients With PSA Relapse

International Journal of Radiation Oncology Biology Physics

Volumn 75, Issue 4, 2009, Pages 983-989

  Choo, Richard ^a   Danjoux, Cyril ^b   Gardner, Sandra ^b   Morton, Gerard ^b   Szumacher, Ewa ^b   Loblaw, D Andrew ^b   Cheung, Patrick ^b   Pearse, Maria ^c  

^a MAYO CLINIC   (United States)

^b DEPARTMENT OF RADIATION ONCOLOGY   (Canada)

^c AUCKLAND CITY HOSPITAL   (New Zealand)

Author keywords

prostate cancer; PSA relapse after surgery; Salvage radiotherapy plus androgen suppression

Indexed keywords

ANDROGEN SUPPRESSION; COMBINED TREATMENT; COX REGRESSION ANALYSIS; KAPLAN-MEIER METHOD; OVERALL SURVIVAL RATES; PROGNOSTIC FACTORS; PROSPECTIVE STUDY; PROSTATE CANCER; PROSTATE CANCERS; PROSTATE SPECIFIC ANTIGEN; RADICAL PROSTATECTOMY; SALVAGE RADIOTHERAPY; SALVAGE TREATMENT;

RADIOTHERAPY; REGRESSION ANALYSIS; SURGERY;

PEELING;

BUSERELIN ACETATE; NILUTAMIDE; PROSTATE SPECIFIC ANTIGEN; ANTIANDROGEN; BUSERELIN; IMIDAZOLIDINE DERIVATIVE;

ADJUVANT THERAPY; ADULT; AGE DISTRIBUTION; AGED; ANDROGEN DEPRIVATION THERAPY; ANTIGEN DETECTION; ARTICLE; CANCER ADJUVANT THERAPY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER RELAPSE; CANCER SURGERY; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DIZZINESS; DRUG EFFICACY; DRUG WITHDRAWAL; FOLLOW UP; GLEASON SCORE; HOT FLUSH; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CANCER; PROSTATECTOMY; PROTEIN BLOOD LEVEL; RECURRENCE RISK; THERAPY EFFECT; TREATMENT DURATION; TREATMENT RESPONSE; BLOOD; DRUG ADMINISTRATION; METHODOLOGY; MIDDLE AGED; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PILOT STUDY; PROSPECTIVE STUDY; PROSTATE TUMOR; REGRESSION ANALYSIS; SALVAGE THERAPY; SURVIVAL RATE; TIME; TUMOR RECURRENCE;

AGED; ANDROGEN ANTAGONISTS; BUSERELIN; DRUG ADMINISTRATION SCHEDULE; FOLLOW-UP STUDIES; HUMANS; IMIDAZOLIDINES; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PILOT PROJECTS; PROSPECTIVE STUDIES; PROSTATE-SPECIFIC ANTIGEN; PROSTATECTOMY; PROSTATIC NEOPLASMS; REGRESSION ANALYSIS; SALVAGE THERAPY; SURVIVAL RATE; TIME FACTORS;

EID: 70449711684     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2008.12.049     Document Type: Article

References (23)

1. Medini D., Medini I., Reddy P.K., et al. Delayed/salvage radiation therapy in patients with elevated prostate specific antigen levels after radical prostatectomy. Cancer 78 (1996) 1254-1259
2. Crane C.H., Rich T.A., Read P.W., et al. Preirradiation PSA predicts biochemical disease-free survival in patients treated with postprostatectomy external beam irradiation. Int J Radiat Oncol Biol Phys 39 (1997) 681-686
3. Do T., Parker R.G., Do C., et al. Salvage radiotherapy for biochemical and clinical failures following radical prostatectomy. Cancer J Sci Am 4 (1998) 324-330
4. Cadeddu J.A., Partin A.W., DeWeese T.L., et al. Long-term results of radiation therapy for prostate cancer recurrence following radical prostatectomy. J Urol 59 (1998) 173-178
5. Schild S.E. Radiation therapy after prostatectomy: Now or later?. Semin Radiat Oncol 8 (1998) 132-139
6. Leventis A.K., Shariat S.F., Kattan M.W., et al. Prediction of response to salvage radiation therapy in patients with prostate cancer recurrence after radical prostatectomy. J Clin Oncol 19 (2001) 1030-1039
7. Stephenson A.J., Shariat S.F., Zelefsky M.J., et al. Salvage radiotherapy for recurrent prostate cancer after radical prostatectomy. JAMA 291 (2004) 1325-1332
8. Pazona J.F., Han M., Hawkins S.A., et al. Salvage radiation therapy for prostate specific antigen progression following radical prostatectomy: 10-year outcome estimates. J Urol 174 (2005) 1282-1286
9. Buskirk S.J., Pisansky T.M., Schild S.E., et al. Salvage radiotherapy for isolated prostate specific antigen increase after radical prostatectomy: Evaluation of prognostic factors and creation of a prognostic scoring system. J Urol 176 (2006) 985-990
10. Choo R., Hruby G., Hong J., et al. The (in)-efficacy of salvage radiotherapy for rising PSA or clinically isolated local recurrence following radical prostatectomy. Int J Rad Oncol Biol Phys 53 (2002) 269-276
11. De Meerleer G., Fonteyne V., Meersschout S., et al. salvage intensity-modulated radiotherapy for rising PSA after radical prostatectomy. Radiother Oncol 89 (2008) 205-213
12. Pearce A., Choo R., Danjoux C., et al. Effect of combined treatment of salvage radiotherapy plus androgen suppression on quality of life in patients with recurrent prostate cancer after radical prostatectomy. Int J Radiat Oncol Biol Phys 65 (2006) 78-83
13. Pearse M., Choo R., Danjoux C., et al. Prospective assessment of gastrointestinal and genitourinary toxicity of salvage radiotherapy for patients with PSA relapse or local recurrence after radical prostatectomy. Int J Radiat Oncol Biol Phys 72 (2008) 792-798
14. Kaplan E.L., and Meier P. Nonparametric estimation from incomplete observations. Am Stat Assoc J 53 (1958) 457-481
15. Cox D.R. Regression models and life tables. J Royal Stat Soc B34 (1972) 187-220
16. Wu J.J., King S.C., Montana G.S., et al. The efficacy of post prostatectomy radiotherapy in patients with an isolated elevation of serum prostate-specific antigen. Int J Radiat Oncol Biol Phys 35 (1995) 317-323
17. Forman J.D., Meetze K., Pontes E., et al. Therapeutic irradiation for patients with an elevated post-prostatectomy prostate specific antigen level. J Urol 158 (1997) 1436-1440
18. Katz M.S., Zelefsky M.J., Venkatraman E.S., et al. Predictors of biochemical outcome with salvage conformal radiotherapy after radical prostatectomy for prostate cancer. J Clin Oncol 21 (2003) 483-489
19. Tiguert R., Rigaud J., Lacombe L., et al. Neoadjuvant hormone therapy before salvage radiotherapy for an increasing post-radical prostatectomy serum prostate specific antigen level. J Urol 170 (2003) 447-450
20. Anscher M.S., Clough R., and Dodge R. Radiotherapy for a rising prostate-specific antigen after radical prostatectomy: The first 10 years. Int J Radiat Oncol Biol Phys 48 (2000) 369-375
21. Macdonald O.K., D'Amico A.V., Sadetsky N., et al. Predicting PSA failure following salvage radiotherapy for a rising PSA post-prostatectomy: From the CaPSURE database. Urol Oncol 26 (2008) 271-275
22. Trock B.J., Han M., Freedland S.J., et al. Prostate cancer-specific survival following salvage radiotherapy vs observation in men with biochemical recurrence after radical prostatectomy. JAMA 299 (2008) 2760-2769
23. Stephenson A.J., Scardino P.T., Kattan M.W., et al. Predicting the outcome of salvage radiation therapy for recurrent prostate cancer after radical prostatectomy. J Clin Oncol 25 (2007) 2035-2041